PRESS RELEASE
Arix Bioscience plc
Unaudited NAV for April
LONDON, 11 May 2022: Arix Bioscience plc (“Arix” or the “Company”) (LSE: ARIX), a global venture capital company focused on investing in breakthrough biotechnology companies, announces the unaudited NAV of the Company for date ended 30 April 2022 as follows:
|
Date
|
NAV Breakdown
|
Total NAV
|
NAV per share
|
|
Listed Portfolio
|
Unlisted Portfolio
|
Cash
|
Other Interests
|
|
30-Apr-22
(unaudited)
|
£36.3m
|
£57.7m
|
£132.6m
|
£2.8m
|
£229.4m
|
£1.78
|
[ENDS]
Enquiries
For more information on Arix, please contact:
Arix Bioscience plc
+44 (0)20 7290 1050
ir@arixbioscience.com
Powerscourt Group
Sarah MacLeod, Ibrahim Khalil, Nick Johnson
+44 (0)20 7250 1446
arix@powerscourt-group.com
About Arix Bioscience plc
Arix Bioscience plc is a global venture capital company focused on investing in breakthrough biotechnology companies around cutting-edge advances in life sciences.
We collaborate with exceptional entrepreneurs and provide the capital, expertise and global networks to help accelerate their ideas into important new treatments for patients. As a listed company, we are able to bring this exciting growth phase of our industry to a broader range of investors. www.arixbioscience.com
.